Altimmune Inc (ALT)
12.92
+0.89 +7.40%
NASDAQ
Sep 25, 20:00
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 4.154M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.19 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -35.69M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -2.32K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 425.22M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 48.85 |
| PE Ratio | -- |
| Price to Book Value | 5.347 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.0079 |
| Free Cash Flow (Quarterly) | -7.253M |
| Return on Equity | Upgrade |
View All ALT News
News
-
WireHeadlineTime (ET)
-
MT Newswires09/25 16:12
-
MT Newswires09/25 14:18
-
PR Newswire09/25 09:31
-
MT Newswires09/25 09:22
-
MT Newswires09/25 08:58
-
MT Newswires09/25 04:40
-
SA Breaking News09/25 03:54
-
SA Breaking News09/24 16:55
-
SA Breaking News09/24 04:03
-
SA Breaking News09/22 05:43
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 11/13/2020 | Misc | Altimmune Inc Third Quarter Earnings Conference Call for 2020 |
| 11/13/2020 | Earnings | Altimmune Inc Third Quarter Earnings for 2020 Release |
| 09/24/2020 10:00 EDT | Misc | Altimmune Inc Annual General Meeting for 2019 |
| 08/12/2020 08:30 EDT | Misc | Altimmune Inc Second Quarter Earnings Conference Call for 2020 |
| 08/12/2020 | Earnings | Altimmune Inc Second Quarter Earnings Result for 2020 |
| 05/14/2020 08:30 EDT | Misc | Altimmune Inc First Quarter Earnings Conference Call for 2020 |
| 05/14/2020 | Earnings | Altimmune Inc First Quarter Earnings Result for 2020 |
| 03/27/2020 08:30 EDT | Misc | Altimmune Inc Fourth Quarter Earnings Conference Call for 2019 |
| 03/27/2020 | Misc | Altimmune Inc Annual Report for 2019 |
| 03/25/2020 16:30 EDT | Earnings | Altimmune Inc Fourth Quarter Earnings Results for 2019 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.altimmune.com
- Investor Relations URL: http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome
- HQ State/Province: Maryland
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Blend
- Next Earnings Release: Nov. 13, 2020
- Last Earnings Release: Aug. 12, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: Jan. 20, 2017
- Description: Altimmune Inc is a United States-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 12.92 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ALT Tweets Stocktwits
Advertisement
